Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Melemed SA"'
Autor:
Tabernero J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jtabernero@vhio.net., Hozak RR; Oncology, Eli Lilly and Company, Indianapolis, USA., Yoshino T; Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan., Cohn AL; Medical Oncology, Rocky Mountain Cancer Center/US Oncology, Denver, USA., Obermannova R; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic., Bodoky G; Oncology, Szent László Hospital, Budapest, Hungary., Garcia-Carbonero R; Medical Oncology Department, Hospital Universitario 12 de Octubre, CNIO; CIBERONC, Universidad Complutense, Madrid, Spain., Ciuleanu TE; Medical Oncology, Prof. Dr. I. Chiricuţă Institute of Oncology, Cluj-Napoca, Romania., Portnoy DC; Oncology, West Clinic, Memphis, USA., Prausová J; Department of Oncology and Radiotherapy, University Hospital Motol, Prague, Czech Republic., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Siegel RW; Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA., Konrad RJ; Laboratory for Experimental Medicine, Eli Lilly and Company, Indianapolis, USA., Ouyang H; Oncology, Eli Lilly and Company, Indianapolis, USA., Melemed SA; Oncology, Eli Lilly and Company, Indianapolis, USA., Ferry D; Oncology, Eli Lilly and Company, Indianapolis, USA., Nasroulah F; Oncology, Eli Lilly and Company, Argentina., Van Cutsem E; Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium; KU Leuven, Leuven, Belgium.
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 Mar 01; Vol. 29 (3), pp. 602-609.
Autor:
Fuchs CS; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA., Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona 08035, Spain., Tomášek J; Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno 656 53, Czech Republic., Chau I; Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK., Melichar B; Onkologicka klinika, Lekarska fakulta Univerzity Palackeho a Fakultni nemocnice, I.P. Pavlova, 6, Olomouc 779 00, Czech Republic., Safran H; Brown University Oncology Research Group, 164 Summit Avenue, Fain 3, Providence, Rhode Island 02906, USA., Tehfe MA; Centre Hospitalier de Montréal, 1560 Sherbrooke East St, Montreal, Quebec H2L4M1, Canada., Filip D; Spitalul Judetean de Urgenta, Strada George Coşbuc 31, Baia Mare 430031, Romania., Topuzov E; State Budgetary Educational Institution of Higher Professional Education (SBEIHPE), Northwest State Medical University na II Mechnikov, Ministry of Healthcare of the Russian Federation, Russia., Schlittler L; Hospital da Cida de Passo Fundo, Rua Tiradentes, 295 Centro, Passo Fundo, 99010-260, Brazil., Udrea AA; Medisprof SRL, P-ta 1 Mai Nr 3, Cluj 400058, Romania., Campbell W; Hospital Herrera Llerandi, 6 Avenida, Guatemala City, Guatemala., Brincat S; Sir Anthony Mamo Oncology Centre, Msida, Malta., Emig M; Lilly Deutschland GmbH, Werner-Reimers-Straße 2, Bad Homburg vor der Höhe 61352, Germany., Melemed SA; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA., Hozak RR; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA., Ferry D; Eli Lilly and Company, 440 Route 22 East, Bridgewater, New Jersey 08807, USA., Caldwell CW; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA., Ajani JA; The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, Texas 77030, USA.
Publikováno v:
British journal of cancer [Br J Cancer] 2016 Oct 11; Vol. 115 (8), pp. 974-982. Date of Electronic Publication: 2016 Sep 13.
Autor:
Zinner RG; Department of Investigational Cancer therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas; †Global Diversity/Med Affairs, Eli Lilly and Company, Indianapolis, Indiana; ‡Medical Oncology, Tennessee Oncology, Nashville, Tennessee; §Hematology/Oncology, Florida Cancer Specialists, Fort Myers, Florida; •Medical Oncology, Highlands Oncology Group, Fayetteville, Arkansas; ¶Hematology-Medical Oncology, Oncology Heamatology Care Inc., Blue Ash, Ohio; #Hematology & Oncology, Internal Medicine, ACRC/Arizona Clinical Research Center, Arizona Oncology, Tucson, Arizona; **Hematology and Oncology, Michigan State University, East Lansing, Michigan; ††Northeast Georgia Cancer Care, University of Georgia Health Sciences University, Athens, Georgia; ‡‡Statistics Oncology, §§CDK4/6 Product Team, GPORWE-Oncology, ¶¶Oncology-Global Strategic Plan, ##Oncology-Early Phase, ***US Med Affairs and Late Phase Prod Dev, †††Global Medical Communications-Oncology, and ‡‡‡Global Med Affairs & Late Phase Prod Dev, Eli Lilly and Company, Indianapolis, Indiana; §§§Department of Medicine, Oncology Division, Washington University Medical School, St. Louis, Missouri; and ••Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona., Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2015 Jan; Vol. 10 (1), pp. 134-42.
Autor:
Holzer TR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America., Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, Ackermann BL, Konrad RJ, Nasir A
Publikováno v:
PloS one [PLoS One] 2013 Nov 14; Vol. 8 (11), pp. e80292. Date of Electronic Publication: 2013 Nov 14 (Print Publication: 2013).